Skip to content
Clinical Trials – home
Verifiedinfo

Samodzielny Publiczny Zaklad Opieki Zdrowotnej Szpital Uniwersytecki W Krakowie

Poland Ul. Botaniczna 3, 31-503 Cracow, Poland

  • 93 trials recruiting
  • Hereditary angioedema · Chronic inflammatory demyelinating polyradiculoneuropathy · Breast cancer
  • Adults and children

About Specializations

Samodzielny Publiczny Zaklad Opieki Zdrowotnej Szpital Uniwersytecki W Krakowie in Cracow, Poland specialises in clinical trials of conditions such as Hereditary angioedema, Chronic inflammatory demyelinating polyradiculoneuropathy, Breast cancer, Hereditary angioedema with C1 esterase inhibitor deficiency, and other specialisations. This site conducts important research.

Main research areas of the site

Ophthalmology and Eye Diseases

At Samodzielny Publiczny Zaklad Opieki Zdrowotnej Szpital Uniwersytecki w Krakowie, the ophthalmology department is active in trials focused on diabetic macular edema, age-related macular degeneration, uveitic macular edema, and thyroid eye disease. These studies are designed to evaluate new treatments and compare them with current care, with the goal of improving vision and slowing disease progression.

  • Testing new therapies for retinal and inflammatory eye conditions
  • Evaluating treatments for vision loss in diabetic eye disease
  • Studying options for thyroid eye disease and related orbital inflammation

The site’s strong eye-disease focus reflects its clinical specialization in both ophthalmology and ocular oncology.

Oncology and Hematologic Malignancies

Many trials at this hospital investigate cancers of the blood and solid tumors, including breast cancer, lymphoma, acute myeloid leukemia, multiple myeloma, prostate cancer, and gastrointestinal cancers. The research mainly aims to improve treatment effectiveness, extend survival, and find better options for patients with advanced or relapsed disease.

  • Assessing novel combinations for breast cancer, including hormone receptor-positive and triple-negative disease
  • Studying therapies for lymphoma, myelofibrosis, and other hematologic malignancies
  • Evaluating treatment strategies for advanced gastrointestinal, liver, ovarian, and urothelial cancers

Overall, the oncology portfolio is broad and includes both targeted treatments and immune-based approaches across multiple cancer types.

Cardiovascular, Stroke, and Metabolic Diseases

Clinical research in cardiovascular diseases includes heart failure, atrial fibrillation, myocardial infarction, hypertension, and stroke prevention. Additional studies address diabetes mellitus, chronic kidney disease, and other metabolic problems, with a focus on better control of risk and prevention of serious complications.

  • Testing approaches to reduce stroke risk in people with atrial fibrillation or after recent ischemic events
  • Evaluating treatments for heart failure and blood pressure that remains difficult to control
  • Studying therapies for type 2 diabetes and related metabolic disorders

These trials show a clear interest in preventing cardiovascular events while also addressing common chronic comorbidities.

Neurology and Autoimmune Disorders

The site also conducts research in neurological diseases and immune-mediated conditions, including multiple sclerosis, myasthenia gravis, epilepsy, autoimmune encephalitis, and amyotrophic lateral sclerosis. These studies are aimed at improving symptom control, reducing disease activity, and finding safer long-term treatment options.

  • Exploring therapies for relapsing and progressive multiple sclerosis
  • Evaluating treatments for myasthenia gravis and other neuromuscular disorders
  • Studying seizure control in refractory epilepsy and emergency seizure conditions

This area combines neurology with immunology, reflecting a strong interest in disorders driven by immune dysfunction.

Endocrinology, Rare Diseases, and Immune System Disorders

Research here extends to hormonal diseases, genetic conditions, and rare immune disorders such as congenital adrenal hyperplasia, hypoparathyroidism, hereditary angioedema, and Niemann-Pick disease type C1. The purpose of these trials is often to improve disease control, reduce symptoms, and better understand long-term safety and effectiveness of emerging therapies.

  • Studying treatment options for rare endocrine disorders and calcium regulation problems
  • Evaluating new approaches for hereditary angioedema and other complement-related diseases
  • Investigating therapies for inherited metabolic and genetic diseases

These trials highlight the site’s involvement in specialized research for patients with uncommon and often complex conditions.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Ul. Botaniczna 331-503 CracowPoland
Recruiting now
93 trials
Conditions studied
168
Partner status
Verified

More sites in CracowPoland

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

242 clinical trials

Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Anifrolumab
  • Sponsor:AstraZeneca AB
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:BioNTech SE
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Empasiprubart
  • Sponsor:Argenx
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:NAVENIBART
  • Sponsor:Astria Therapeutics Inc.
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:Exelixis Inc.
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Sponsor:Alexion Pharmaceuticals Inc.
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Sponsor:Diamedica Therapeutics Inc.
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Ruxolitinib
  • Sponsor:Ryvu Therapeutics S.A.
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Dimeticone
  • Sponsor:Novartis Pharma AG
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Clostridium Botulinum, Neurotoxin Serotype A/B
  • Sponsor:Ipsen Innovation
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Baxdrostat
  • Sponsor:AstraZeneca AB
Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Keto-Leucine Calcium
  • Sponsor:Agencja Badań Medycznych
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).